A huge boost to treatment for the Hepatitis C virus (HCV) is on the horizon, as two pharmaceutical companies are set to release new drugs to market. And with development complete, the marketing war begins. Forbes reports that Merck has won FDA approval for Victrelis, and the drug, which costs $35,000 for the course of treatment, will hit pharmacies' shelves by next week, along with the company's targeted marketing campaign.
Read More